retatrutide dosing phase 2 trial VisualAbstract: reduces body weight by 17.5% in patients with obesity retatrutide triple agonist phase 2

Because of their glucose lowering effects, therapies that enhance incretin actions through inhibiting degradation of endogenous incretins or through activation of the GLP-1 receptor are now in use for the treatment of type 2 diabetes ( ATP channels and in postprandial hypoglycemia after gastrointestinal surgery, where the delivery of nutrients to the small intestine is altered resulting in both hyperglycemia and an exaggerated secretion of GLP-1

PubMed: 11600700 Ipamorelin: A Selective Growth Hormone Secretagogue with Minimal Prolactin and Cortisol Effects human pilot Raun K, Hansen BS, Johansen NL, et al

Individual TMAO trajectories are shown in Supplementary Figure 9

& Owsianik, G